Metabolic & Cardiometabolic
lipoprotein(a) causes cardiovascular disease
In plain terms: Is high Lp(a) an actual cause of heart disease, and can new drugs lower it?
Strong support Metabolic & Cardiometabolic 🔬 Includes disconfirming
RefutedContestedStrong support
consensus score 0.96
Genetics (Mendelian randomization) and large epidemiology show Lp(a) is causally atherogenic — likely more potent per particle than LDL — and siRNA/antisense/oral agents now cut it up to ~80-99%, though cardiovascular-outcome trials are still pending.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
13 support 1 contradict 0 tested null 0 mixed · 14 sources, 13 independent groups
What the evidence shows
Mendelian randomisation and large-scale epidemiology agree that lipoprotein(a) is causally atherogenic, probably more potent per particle than LDL: LPA variants that raise Lp(a) raise coronary disease risk independently of LDL cholesterol. What is still missing is outcome data from the drugs that lower it, so the causal case rests on genetics, not trials.
The evidence (16)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Lee MP, Koenigsberg SH, Anwar MY, Raffield LM, Lin Z, Ballou AF, Booth JN, Davy-Mendez T, Kassahun H, Kent ST, López JAG, Monda KL, North KE, Yarosh R, Ballantyne CM, Graff M, Avery CL 2026 · JACC Adv | observational | supports | high | Mendelian randomization showed Lp(a) exerts a causal effect on coronary artery disease independent of LDL-C. |
| Tognola C, Bernasconi DP, Rebora P, Intravaia RCM, Mancusi C, Visco V, Cesaro A, Golia E, Ilaria F, Merlini P, Ardissino M, Inglese E, Danesi R, Oliva F, Andreano A, Rognoni M, Russo A, Calabrò P, De Luca N, Giannattasio C, Maloberti A 2026 · High Blood Press Cardiovasc Prev | observational | contradicts | low | Italian primary-prevention cohort, low CV risk, 747 with Lp(a) measured (isoform-insensitive assay), 725 with follow-up, median 10 years, 71 CV events. CV events HR per 10 mg/dL Lp(a) 1.01 (95% CI 0.97-1.05) unadjusted and 1.01 (0.96-1.05) adjusted for age, sex, diabetes, LDL, statins, antihypertensives, GFR; no difference in cumulative incidence at the 50 mg/dL cut-off. Clean null on CV events, but few events and a low-risk sample limit precision; observational association, not a causal test. Subclinical organ-damage nulls are off-object. |
| Cereda A, Stracqualursi M, Rocchetti M, Mariani M, Carlà M, Franchina AG, Carelli M, Sticchi A, Galli M, Lucreziotti S 2026 · J Clin Med | meta-analysis | supports | moderate | Systematic review/meta-analysis of 26 studies found elevated Lp(a) associated with higher MACE after PCI (HR 1.4, 95% CI 1.2-1.7), restenosis (OR 3.23), target vessel revascularization (OR 2.6), and aortic valve calcification. |
| Hsu HY, Fan HY, Tsai MC, Lai CJ, Hwang LC, Chien KL 2026 · Circ J | observational | supports | moderate | Combined observational and Mendelian randomization analyses supported a causal, largely linear association between Lp(a) and atherosclerotic cardiovascular disease. |
| Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M, PROCARDIS Consortium 2009 · N Engl J Med | observational | supports | high | PROCARDIS: LPA SNPs (rs10455872, rs3798220) strongly and causally associated with coronary disease via raised Lp(a). |
| Chen X, Jin Z, Gong L, Keng S, Zhang Y, Zhang Y, Long C, Pu Y, Zhang M, Wang S, Zhang B 2026 · Front Endocrinol (Lausanne) | meta-analysis | tested-null | moderate | Off-scope: measured Lp(a) vs incident type 2 diabetes, not cardiovascular disease. 'Pooled random-effects meta-analysis demonstrated an inverse association between Lp(a) and the risk of T2D development (RR = 0.73, 95% CI: 0.56, 0.96, I 2 = 76.6%' from 7 prospective cohorts (n=49,451). Pools primary cohorts itself, so not a review, but the outcome is T2D. |
| Björnson E, Adiels M, Taskinen MR, Burgess S, Chapman MJ, Packard CJ, Borén J 2024 · J Am Coll Cardiol | observational | supports | high | ApoB-based genetic (UK Biobank): per-particle, Lp(a) markedly MORE atherogenic than LDL — supports the more-atherogenic-per-particle claim. |
| Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, Willeit P, Young R, Surendran P, Karthikeyan S, Bolton TR, Peters JE, Kamstrup PR, Tybjærg-Hansen A, Benn M, Langsted A, Schnohr P, Vedel-Krogh S, Kobylecki CJ, Ford I, Packard C, Trompet S, Jukema JW, Sattar N, Di Angelantonio E, Saleheen D, Howson JMM, Nordestgaard BG, Butterworth AS, Danesh J, European Prospective Investigation Into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) Consortium 2018 · JAMA Cardiol | observational | supports | high | Genetic analysis: ~100 mg/dL Lp(a) lowering needed for CHD benefit comparable to ~40 mg/dL LDL — quantifies causal Lp(a) effect. |
| Nicholls SJ, Nissen SE, Fleming C, Urva S, Suico J, Berg PH, Linnebjerg H, Ruotolo G, Turner PK, Michael LF 2023 · JAMA | RCT | supports | moderate | Phase 1 oral muvalaplin: well tolerated, reduced Lp(a) up to ~65% — proof-of-concept for oral Lp(a) lowering. |
| Kaur G, Rosenson RS, Gencer B, López JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Park JG, Wang H, Wu Y, Kassahun H, Sabatine MS, O'Donoghue ML 2025 · Eur Heart J | RCT | supports | high | Phase 2 olpasiran siRNA: lowered Lp(a) by ~95-99% across baseline levels; surrogate endpoint only, outcome trial OCEAN(a)-Outcomes ongoing. |
| He Y, Liu J, Zhuang J, Hu H 2026 · Clin Cardiol | meta-analysis | supports | moderate | Dose-response meta-analysis of 5 prospective cohorts (400,631 participants) found elevated Lp(a) associated with increased heart failure risk (HR 1.34, 95% CI 1.14-1.59), with stronger effect at Lp(a) >=50 mg/dL (HR 1.68) and a nonlinear dose-response relationship. |
| Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG 2009 · JAMA | observational | supports | high | Mendelian randomization (Copenhagen): genetically elevated Lp(a) via LPA KIV-2 causally raises myocardial infarction risk. |
| Nicholls SJ, Ni W, Rhodes GM, Nissen SE, Navar AM, Michael LF, Haupt A, Krege JH 2025 · JAMA | RCT | supports | moderate | Phase 2 oral muvalaplin: placebo-adjusted Lp(a) reductions up to ~86% over 12 wk; no outcome data yet, oral small molecule. |
| Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S, Guerriero J, Viney NJ, O'Dea L, Witztum JL, AKCEA-APO(a)-LRx Study Investigators 2020 · N Engl J Med | RCT | supports | high | Phase 2 pelacarsen (apo(a) antisense): dose-dependent Lp(a) reduction up to ~80% in CVD patients; outcomes (Lp(a)HORIZON) pending. |
| Daghlas I, Georgakis MK, Arsenault BJ, Kim AS, Burgess S, Gill D 2026 · J Am Heart Assoc | observational | supports | high | Mendelian randomization supported a causal Lp(a) effect on large-artery/atherosclerotic stroke but not on all cerebrovascular subtypes. |
| Wu AX, Wang XJ, Zhao C, Hu JQ, Li JW, Xu Y, Li Y, Liu S 2026 · Pharmacol Res | meta-analysis | supports | high | Network meta-analysis of 25 RCTs showed siRNA and antisense agents lower Lp(a) by 54-92%, confirming the new drugs can potently reduce Lp(a). |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.